Mindbio launches intoxication detection tech in U.S.

Executive Summary

• Mindbio Therapeutics Corp. has launched an extended showcase of its proprietary voice and AI-powered intoxication detection technology in the United States.
• The company simultaneously listed its common shares for trading on the OTCQB market.
• The technology utilizes over 50 million data points to predict alcohol and hallucinogenic drug intoxication with high accuracy by analyzing human voice patterns, aiming to serve industries such as mining, aviation, construction, and law enforcement.

Key Details

• Technology Core: The solution is activated by voice and powered by AI, using proprietary algorithms based on data from drug and alcohol clinical trials.
• Capabilities:
  • Predicts intoxication levels for alcohol and hallucinogenic drugs.
  • Estimates actual blood alcohol concentration (BAC) levels.
  • Aims to expand detection to other prohibited drugs that are difficult to detect at scale or require specialized equipment.
• Product Launch: The "Booze AI" app is scheduled for a successful launch in 2025, which will estimate BAC levels.
• Target Markets:
  • Workplace environments (mining, aviation, construction) where regulatory drug/alcohol testing is mandated.
  • Call centers, mental health sectors, and law enforcement.
• Enterprise Development: The company is developing an enterprise version and a new platform-level technology for broader health prediction using human voice analytics.
• Market Listing: The showcase coincides with the listing of Mindbio's common shares on the OTCQB market.
• CEO Statement: CEO Justin Hanka described the technology as an "exciting new non-invasive diagnostic tool" with broad implications for detecting internal health, wellness, and disease states.

Notable Quotes

• "Our voice and AI powered intoxication detection technology is an exciting new non-invasive diagnostic tool that has broad implications for the detection of internal health, wellness and disease states." — Justin Hanka, CEO